Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Quest Diagnostics (DGX) insider trading

Insider activity, historical context and SEC filings · data through Nov 20, 2026

Health CareDGX

Closing price · Nov 19, 2026 $259.06 -0.2% on the day · +41.7% over 12 months 52-week range $170.62 – $262.21
Get DGX alerts
Open-market purchases0 insidersno buys · last 12 months
Insiders selling9last 12 months
Reported sales$48.8M40 of 43 recent sales pre-planned (10b5-1)
In 15 seconds

No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.

Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.
  • Next earnings expected around Jan 21, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Latest open-market trade

Sale Michael J. Deppe, Svp, Corp. Controller & Cao sold 6,261 shares at $260.17 ($1.6M).

Trade date
Nov 13, 2026
Disclosed to the SEC
Nov 16, 2026
Type
Pre-planned sale, 10b5-1 (code S)

Read the original SEC filing ↗All DGX insider trades ↓

Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.

DGX insider transactions (Form 4)

Open-market purchases and sales. 112 grants, option exercises and tax withholdings are not shown.

Filed Insider Type Shares Price Value Since Score
Nov 16SEC Michael J. DeppeSvp, Corp. Controller & Cao Sell Plan 6,26135,203 held (−15%) $260.17 $1.6M -0.4% —
Nov 16SEC Michael J. DeppeSvp, Corp. Controller & Cao Sell Plan 5,51535,203 held (−14%) $260.17 $1.4M -0.4% —
Nov 12SEC Patrick PlewmanSvp For Diagnostic Services Sell Plan 6,79315,334 held (−31%) $257.34 $1.7M +0.7% —
Nov 12SEC Patrick PlewmanSvp For Diagnostic Services Sell Plan 4,27415,334 held (−22%) $257.34 $1.1M +0.7% —
Nov 12SEC Patrick PlewmanSvp For Diagnostic Services Sell Plan 65014,684 held (−4%) $257.34 $167K +0.7% —
Nov 5SEC Catherine T. DohertyPresident Sell Plan 5,99084,246 held (−7%) $246.26 $1.5M +5.2% —
Nov 5SEC Catherine T. DohertyPresident Sell Plan 3,81890,236 held (−4%) $245.45 $937K +5.5% —
Nov 5SEC Catherine T. DohertyPresident Sell Plan 3,00477,733 held (−4%) $249.40 $749K +3.9% —
Nov 5SEC Catherine T. DohertyPresident Sell Plan 2,90771,949 held (−4%) $251.24 $730K +3.1% —
Nov 5SEC Catherine T. DohertyPresident Sell Plan 2,87774,856 held (−4%) $250.49 $721K +3.4% —
Nov 5SEC Catherine T. DohertyPresident Sell Plan 2,35880,737 held (−3%) $248.38 $586K +4.3% —
Nov 5SEC Catherine T. DohertyPresident Sell Plan 1,15183,095 held (−1%) $246.98 $284K +4.9% —
Oct 28SEC Gary M. PfeifferDirector Sell Plan 1,20329,802 held (−4%) $243.00 $292K +6.6% —
Sep 3SEC J. E. DavisCEO, President Sell Plan 10,000122,423 held (−8%) $242.72 $2.4M +6.7% —
Aug 31SEC Michael E. PrevoznikGeneral Counsel Sell Plan 16,01044,224 held (−27%) $242.88 $3.9M +6.7% —
Aug 31SEC Michael E. PrevoznikGeneral Counsel Sell Plan 6,23737,987 held (−14%) $243.63 $1.5M +6.3% —
Aug 31SEC Michael E. PrevoznikGeneral Counsel Sell Plan 43037,557 held (−1%) $244.51 $105K +5.9% —
Jul 29SEC Mark E. DelaneySvp & Chief Commercial Officer Sell Plan 1,60010,335 held (−13%) $235.18 $376K +10.2% —
Jun 8SEC Karthik KuppusamySvp, Clinical Solutions Sell Plan 8,14713,510 held (−38%) $200.00 $1.6M +29.5% —
Jun 2SEC J. E. DavisCEO, President Sell Plan 10,000132,423 held (−7%) $194.14 $1.9M +33.4% —
Mar 6SEC Catherine T. DohertyEvp, Regional Businesses Sell Plan 5,55867,122 held (−8%) $206.21 $1.1M +25.6% —
Mar 6SEC Michael E. PrevoznikGeneral Counsel Sell Plan 3,87837,557 held (−9%) $206.21 $800K +25.6% —
Mar 6SEC Patrick PlewmanSvp For Diagnostic Services Sell Plan 2,85515,198 held (−16%) $206.21 $589K +25.6% —
Mar 6SEC Karthik KuppusamySvp, Clinical Solutions Sell 2,62813,441 held (−16%) $204.86 $538K +26.5% —
Mar 4SEC J. E. DavisCEO, President Sell Plan 10,000117,185 held (−8%) $212.52 $2.1M +21.9% —
Mar 4SEC Catherine T. DohertyEvp, Regional Businesses Sell Plan 63267,122 held (−1%) $207.73 $131K +24.7% —
Mar 4SEC Michael E. PrevoznikGeneral Counsel Sell Plan 52637,557 held (−1%) $207.73 $109K +24.7% —
Mar 4SEC Patrick PlewmanSvp For Diagnostic Services Sell Plan 41015,198 held (−3%) $207.73 $85K +24.7% —
Feb 20SEC Catherine T. DohertyEvp, Regional Businesses Sell Plan 1,43368,402 held (−2%) $204.83 $294K +26.5% —
Feb 20SEC Michael E. PrevoznikGeneral Counsel Sell Plan 1,11138,371 held (−3%) $204.83 $228K +26.5% —
Feb 20SEC Patrick PlewmanSvp For Diagnostic Services Sell Plan 95815,838 held (−6%) $204.83 $196K +26.5% —
Feb 17SEC Catherine T. DohertyEvp, Regional Businesses Sell Plan 10,57383,660 held (−11%) $205.21 $2.2M +26.2% —
Feb 17SEC Catherine T. DohertyEvp, Regional Businesses Sell Plan 10,12273,538 held (−12%) $206.37 $2.1M +25.5% —
Feb 17SEC Catherine T. DohertyEvp, Regional Businesses Sell Plan 3,50070,038 held (−5%) $207.08 $725K +25.1% —
Feb 17SEC Catherine T. DohertyEvp, Regional Businesses Sell Plan 1,61968,419 held (−2%) $208.21 $337K +24.4% —
Feb 17SEC Catherine T. DohertyEvp, Regional Businesses Sell Plan 35168,068 held (−1%) $209.10 $73K +23.9% —
Feb 12SEC Patrick PlewmanSvp For Diagnostic Services Sell Plan 5,66215,381 held (−27%) $204.00 $1.2M +27.0% —
Nov 28SEC J. E. DavisCEO, President Sell Plan 41,004125,227 held (−25%) $192.27 $7.9M +34.7% —
Nov 28SEC J. E. DavisCEO, President Sell Plan 9,342166,231 held (−5%) $191.59 $1.8M +35.2% —
Nov 28SEC J. E. DavisCEO, President Sell Plan 4,747120,480 held (−4%) $192.97 $916K +34.2% —
Nov 28SEC Vicky B. GreggDirector Sell 1,25017,037 held (−7%) $191.76 $240K +35.1% —
Nov 20SEC Mark E. DelaneySvp & Chief Commercial Officer Sell Plan 7,9467,530 held (−51%) $187.35 $1.5M +38.3% —
Oct 24SEC Gary M. PfeifferDirector Sell 1,48229,431 held (−5%) $182.40 $270K +42.0% —
Historical context

Similar past setups: not applicable. DGX has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →

Play with DGX in the Research Lab

DGX has no open-market insider buys in the last 12 months. Try the tools with any setup.

All tools →

Quick backtest: did buys like this beat the market?

Insiders buying
CEO or CFO
Dollar size
Stock before

Tap a setting to see how 6,290 past insider buys did.

Open the full Backtester →

Share price and insider trades

DGX closeInsider buyInsider sale
150200250300DecJan 2026FebMarAprMayJunJulAugSepOctNovEEarnings release filed 2026-01-12EEarnings release filed 2026-02-10EEarnings release filed 2026-04-21EEarnings release filed 2026-07-23EEarnings release filed 2026-10-22Sold $292,329 on 2026-10-26 · Gary M. PfeifferSold $325,721 on 2026-03-03 · Catherine T. Doherty, Michael E. Prevoznik, Patrick PlewmanSold $376,288 on 2026-07-28 · Mark E. DelaneySold $538,372 on 2026-03-04 · Karthik KuppusamySold $717,315 on 2026-02-19 · Catherine T. Doherty, Michael E. Prevoznik, Patrick PlewmanSold $1,155,048 on 2026-02-10 · Patrick PlewmanSold $1,629,400 on 2026-06-04 · Karthik KuppusamySold $1,941,400 on 2026-06-01 · J. E. DavisSold $2,125,200 on 2026-03-02 · J. E. DavisSold $2,427,200 on 2026-09-01 · J. E. DavisSold $2,534,527 on 2026-03-05 · Catherine T. Doherty, Michael E. Prevoznik, Patrick PlewmanSold $3,015,253 on 2026-11-09 · Patrick PlewmanSold $3,063,762 on 2026-11-13 · Michael J. DeppeSold $5,393,815 on 2026-02-13 · Catherine T. DohertySold $5,482,442 on 2026-11-03 · Catherine T. DohertySold $5,513,083 on 2026-08-28 · Michael E. PrevoznikSold $10,829,460 on 2025-11-25 · J. E. Davis, Vicky B. Gregg
Bought, 12 months$0
Sold, 12 months$48.8M
Insiders buying0
Insiders selling9

Quest Diagnostics insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 9 sold $48.8M of DGX stock on the open market; P/E 27.6 vs. a sector median of 25.0.

By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this

DGX insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q4 2025: $12.6M sold (6 trades)Q4 2025Q1 2026: $12.8M sold (17 trades)Q1 2026Q2 2026: $3.6M sold (2 trades)Q2 2026Q3 2026: $8.3M sold (5 trades)Q3 2026Q4 2026: $11.9M sold (13 trades)Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0$11.9M13
Q3 2026—0$8.3M5
Q2 2026—0$3.6M2
Q1 2026—0$12.8M17
Q4 2025—0$12.6M6

Valuation, profit and volume

P/E (trailing)27.6Sector median 25.0
Volume vs. 50-day0.8×Last 5 sessions

Source: SEC filings, as of Nov 16, 2026. Volume and paper profit use daily closing prices.

Summary

Over the past 12 months, 0 Quest Diagnostics insiders reported open-market purchases totaling $0, while 9 insiders reported sales totaling $48.8M. 40 of 43 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

DGX earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
Oct 22, 2026 +4.6% None +1.2%S&P -1.7% pending
Jul 23, 2026 -0.8% None +8.6%S&P -1.1% +7.3%
Apr 21, 2026 -0.4% None +3.9%S&P +0.4% -4.3%
Feb 10, 2026 +5.7% None +9.4%S&P -0.3% -4.6%
Jan 12, 2026 -0.8% None +3.6%S&P -0.0% +14.9%
Oct 21, 2025 +6.2% None -4.9%S&P -0.5% +5.6%
Jul 22, 2025 -5.5% None +2.4%S&P +0.9% +5.7%
Apr 22, 2025 -0.9% None +7.2%S&P +4.2% -1.3%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

DGX short selling

Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.

Rising
20%40%60%2026-08-26: 83% of volume sold short2026-08-27: 71% of volume sold short2026-08-28: 64% of volume sold short2026-08-31: 61% of volume sold short2026-09-01: 65% of volume sold short2026-09-02: 54% of volume sold short2026-09-03: 64% of volume sold short2026-09-04: 70% of volume sold short2026-09-08: 55% of volume sold short2026-09-09: 60% of volume sold short2026-09-10: 64% of volume sold short2026-09-11: 59% of volume sold short2026-09-14: 70% of volume sold short2026-09-15: 67% of volume sold short2026-09-16: 84% of volume sold short2026-09-17: 79% of volume sold short2026-09-18: 91% of volume sold short2026-09-21: 81% of volume sold short2026-09-22: 41% of volume sold short2026-09-23: 57% of volume sold short2026-09-24: 61% of volume sold short2026-09-25: 65% of volume sold short2026-09-28: 42% of volume sold short2026-09-29: 43% of volume sold short2026-09-30: 53% of volume sold short2026-10-01: 41% of volume sold short2026-10-02: 35% of volume sold short2026-10-05: 65% of volume sold short2026-10-06: 41% of volume sold short2026-10-07: 68% of volume sold short2026-10-08: 68% of volume sold short2026-10-09: 61% of volume sold short2026-10-12: 29% of volume sold short2026-10-13: 32% of volume sold short2026-10-14: 34% of volume sold short2026-10-15: 34% of volume sold short2026-10-16: 49% of volume sold short2026-10-19: 52% of volume sold short2026-10-20: 42% of volume sold short2026-10-21: 73% of volume sold short2026-10-22: 63% of volume sold short2026-10-23: 76% of volume sold short2026-10-26: 75% of volume sold short2026-10-27: 73% of volume sold short2026-10-28: 66% of volume sold short2026-10-29: 73% of volume sold short2026-10-30: 82% of volume sold short2026-11-02: 78% of volume sold short2026-11-03: 72% of volume sold short2026-11-04: 55% of volume sold short2026-11-05: 70% of volume sold short2026-11-06: 77% of volume sold short2026-11-09: 65% of volume sold short2026-11-10: 63% of volume sold short2026-11-11: 61% of volume sold short2026-11-12: 58% of volume sold short2026-11-13: 58% of volume sold short2026-11-16: 66% of volume sold short2026-11-17: 43% of volume sold short2026-11-18: 49% of volume sold shortAug 26Sep 10Sep 24Oct 8Oct 22Nov 5
Latest (Nov 18): 49%20-day average: 66%Prior 2 months: 56%

This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →

Members of Congress who traded DGX

From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.

All Congress trades →
MemberTradeTradedReportedSince trade
Alan ArmstrongSenate Bought $1,001 - $15,000 Mar 30, 2026Jul 21, 2026 +33.0%
Alan ArmstrongSenate Bought $1,001 - $15,000 Mar 27, 2026Jul 21, 2026 +34.1%

Insiders at Quest Diagnostics

InsiderBoughtSoldLast filingPast buys beat S&PScore
J. E. DavisCEO, President — $17.1M Sep 3, 2026 — —
Catherine T. DohertyPresident — $12.4M Nov 5, 2026 — —
Michael E. PrevoznikGeneral Counsel — $6.6M Aug 31, 2026 — —
Patrick PlewmanSvp For Diagnostic Services — $5.0M Nov 12, 2026 — —
Michael J. DeppeSvp, Corp. Controller & Cao — $3.1M Nov 16, 2026 — —
Karthik KuppusamySvp, Clinical Solutions — $2.2M Oct 23, 2026 — —
Mark E. DelaneySvp & Chief Commercial Officer — $1.9M Nov 5, 2026 — —
Gary M. PfeifferDirector — $563K Oct 28, 2026 — —
Vicky B. GreggDirector — $240K Oct 23, 2026 — —
Subu RamachandranSvp, Regional Businesses — — Nov 5, 2026 — —
Sam SamadCFO, President — — Oct 23, 2026 — —
Timothy L. MainDirector — — Oct 23, 2026 — —
Robert B. CarterDirector — — Oct 23, 2026 — —
Wright Lassiter IIIDirector — — Oct 23, 2026 — —
Timothy M. RingDirector — — May 21, 2026 — —
Denise M. MorrisonDirector — — May 21, 2026 — —
Timothy C. WentworthDirector — — May 21, 2026 — —
Tracey DoiDirector — — May 21, 2026 — —
Luis DiazDirector — — May 21, 2026 — —

Board links: companies that share insiders with DGX

Directors and executives who filed Form 4s for DGX and another company in the last 12 months.

See the map →
  • BDXBecton Dickinson Timothy M. Ring Director here · Director at BDX · latest filing May 21, 2026
  • FTVFortive Wright Lassiter III Director here · Director at FTV · latest filing Oct 23, 2026
  • METMetLife Denise M. Morrison Director here · Director at MET · latest filing May 21, 2026
  • PNRPentair Tracey Doi Director here · Director at PNR · latest filing May 21, 2026
  • VVisa Denise M. Morrison Director here · Director at V · latest filing May 21, 2026

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • KODKodiak Sciences Inc.$181M bought
  • BBTXBambusa Therapeutics, Inc.$52.6M bought
  • WWBWINDWARD BIO GROUP AG$49.8M bought
  • ADRXADARx Pharmaceuticals, Inc.$43.4M bought
  • PEPGPepGen Inc.$43.1M bought
  • LYCALycia Therapeutics, Inc.$38.5M bought

DGX stock: common questions

Are Quest Diagnostics insiders buying DGX stock?

No. No Quest Diagnostics insider reported an open-market purchase of DGX in the past 12 months.

Are Quest Diagnostics insiders selling DGX stock?

9 insiders reported sales worth $48.8M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is DGX's P/E ratio?

DGX trades at about 27.6 times trailing earnings, compared with a median of 25.0 for the Health Care sector.

What is DGX's 52-week range?

Over the past year DGX has traded between $170.62 and $262.21. It last closed at $259.06 on Nov 19, 2026.